Search

everythinglearnresearchcommunity

for

Search:↓

A user mixed 3g of RU58841 with Kirkland Minoxidil and noticed a gooey precipitate forming. They are seeking advice on what went wrong.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user is taking 2.5 mg oral Minoxidil and was prescribed a topical oil with Minoxidil 8%, Dutasteride 0.05%, and Finasteride 0.5%. They are seeking opinions on whether this combination is excessive or appropriate.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

The user has been using dutasteride, minoxidil, and RU58841 for two years but continues to experience excessive hair shedding, despite also taking various supplements and trying other treatments like red light therapy. They are seeking advice and sharing experiences with others facing similar hair loss challenges.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.

Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.

A user started taking 0.625mg oral minoxidil daily for hair loss, increased the dose to 1.25mg, and experienced a significant shed, losing 70% of scalp density. They cannot tolerate finasteride due to side effects but are hopeful for hair regrowth despite the shedding.

The conversation discusses the legitimacy of purchasing Pyrilutamide (KX-826) for hair loss treatment. Users mention using Minoxidil and express interest in waiting for phase 3 trials for safety and efficacy confirmation.

A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.

A user is experiencing scalp flaking from a finasteride/minoxidil topical solution and considers using salicylic acid shampoo to remove propylene glycol residue. Another user suggests trying a leave-in conditioner to address dryness and flaking.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.

Minoxidil bottle developed crystals, possibly due to air exposure, but the trichologist advised not to worry. The user questions the advice, noting the lack of recommendations for finasteride or derma rolling.

A user shared their four-year experience using 0.5mg dutasteride and topical minoxidil once daily for aggressive early hair loss, maintaining their hairline and regrowing hair on the vertex. They've experienced positive social feedback and increased confidence but also deal with dry eyes from dutasteride and worry about its long-term effects and cost.

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

A user experienced heart palpitations and breathing issues while using oral finasteride and minoxidil for hair loss and plans to switch to generic finasteride and topical minoxidil. They also use Nizoral shampoo and are considering a moisturizing shampoo due to dryness and itchiness.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

Hair loss discussion mentions Minoxidil, finasteride, and RU58841 treatments. Regenepure shampoo's ketoconazole ingredient causes confusion due to inconsistent listings.

A 25-year-old experiencing genetic hair loss used minoxidil, biotin, and cystine but stopped due to routine fatigue, leading to worsened hair loss and unwanted body hair growth. They are hesitant about finasteride due to potential side effects and are seeking advice on effective treatments.

Stemoxydine, a hair loss treatment, is reportedly discontinued, with some users suggesting alternatives like a rebranded version with resveratrol that may enhance Minoxidil. Some users express dissatisfaction with the discontinuation and question the product's value.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The user has been using oral minoxidil, dutasteride, and RU58841 but continues to experience hair loss. They seek advice on why the treatments aren't working and if others have had similar experiences.

GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.